| Name | Title | Contact Details |
|---|
Fresno Surgical Hospital (FSH) is a fully-licensed, Joint Commission-accredited hospital that delivers award-winning surgical care and patient satisfaction. We are a physician-owned hospital that focuses solely on providing advanced, affordable surgical care. Each year, FSH serves approximately 12,000 patients in our Central California service area including: Fresno, Madera, Merced, Kings and Tulare Counties. Our patients enjoy a non-traditional, hotel-like setting and a commitment to quality care and patient satisfaction. Twenty-seven private inpatient suites give patients and their families an environment that promotes relaxation, comfort and healing. FSH was founded by two orthopedic surgeons, Alan H. Pierrot, MD and Thomas Thaxter, MD, who had a vision of improving healthcare. Originally named Fresno Surgery Center (FSC), the facility opened as an outpatient surgery center in 1984. Within the first year, FSC was in the top 10 percent of all freestanding outpatient surgery centers in the nation, based on the number of patients served. The center`s approach to patient service was also unique. The rare combination of compassion, hospitality and surgical excellence continues to be our distinguishing factor. We were the first facility in the United States to provide elective surgery and post-surgical care in a non-hospital setting. Overwhelming popularity among patients, surgeons and staff established FSC as the leader in the nationwide trend toward elective surgery facilities. In fact, we have consistently been recognized as a top performer both in the state of California and nationally.
We are a developer, manufacturer and marketer of prefabricated, semi-custom and custom orthoses. Orthomerica is known for providing exceptional customer service, quality, innovation and prompt delivery of orthopaedic braces to the orthotics and
Logistics Health Incorporated is a La Crosse, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
BlueCross BlueShield of Louisiana is a Baton Rouge, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.